American Journal of Neuroradiology, Vol 19, Issue 4 781-786, Copyright © 1998 by American Society of Neuroradiology
ARTICLES |
Recurrent acute transverse myelopathy associated with anticardiolipin antibodies
A Campi, M Filippi, G Comi and G Scotti
Department of Neuroradiology, Scientific Institute H.S. Raffaele, University of Milan, Italy.
In three patients with recurrent episodes of acute transverse myelopathy, spinal MR imaging during each episode showed areas of hyperintensity on proton density- and T2-weighted images with inconsistent contrast enhancement. Cranial MR imaging, laboratory screenings, and CSF analysis showed only increased titers of anticardiolipin antibodies. Although a causative role in neurologic conditions has not been established conclusively, an association between these antibodies and acute transverse myelopathy and its recurrences cannot be ignored.
This article has been cited by other articles:
![]() |
S. Ferreira, D. P. D'Cruz, and G. R. V. Hughes Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology, April 1, 2005; 44(4): 434 - 442. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Sastre-Garriga and X Montalban APS and the brain Lupus, December 1, 2003; 12(12): 877 - 882. [Abstract] [PDF] |
||||
![]() |
O Heinzlef, B Weill, C Johanet, V Sazdovitch, S Caillat-Zucman, E Tournier-Lasserve, and E Roullet Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics J. Neurol. Neurosurg. Psychiatry, May 1, 2002; 72(5): 647 - 649. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Quencer The American Journal of Neuroradiology 1980-1999 Where We Have Been: Where We Are Going AJNR Am. J. Neuroradiol., January 1, 2000; 21(1): 1 - 8. [Full Text] |
||||
![]() |
M. Shakudo, Y. Inoue, and T. Tsutada HTLV-I-Associated Myelopathy: Acute Progression and Atypical MR Findings AJNR Am. J. Neuroradiol., September 1, 1999; 20(8): 1417 - 1421. [Abstract] [Full Text] |
||||



